Bill Haney, Skyhawk CEO (Dave Pedley/Getty Images for SXSW)

Bill Haney's lat­est start­up scores deal from Sanofi, its newest Big Phar­ma part­ner, with $54M up­front

A heav­i­ly fi­nanced biotech look­ing to drug RNA with small mol­e­cules is adding yet an­oth­er com­pa­ny to its Big Phar­ma short­list.

Sky­hawk Ther­a­peu­tics, the biotech head­ed by se­r­i­al en­tre­pre­neur and doc­u­men­tary film­mak­er Bill Haney, an­nounced an ex­clu­sive, back end-heavy col­lab deal Tues­day with Sanofi, which will pri­mar­i­ly fo­cus on yet-undis­closed tar­gets in both im­munol­o­gy and on­col­o­gy. Sanofi agreed to pay $54 mil­lion up­front, and if all the mile­stones are reached, that could add up to over $2 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.